Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 32235883.
- Also identified by DOI 10.1038/s41591-020-0774-y.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).
Medical subject headings
- AIDS Vaccines
- Anti-Retroviral Agents
- HIV Infections
- HIV-1
- Immunogenicity, Vaccine
- Viral Load
- Viral Vaccines